These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 38934347)
61. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. Oomen PE; Schori D; Tögel-Lins K; Acreman D; Chenorhokian S; Luf A; Karden A; Paulos C; Fornero E; Gerace E; Koning RPJ; Galindo L; Smit-Rigter LA; Measham F; Ventura M Int J Drug Policy; 2022 Feb; 100():103493. PubMed ID: 34687992 [TBL] [Abstract][Full Text] [Related]
62. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Young AC; Schwarz E; Medina G; Obafemi A; Feng SY; Kane C; Kleinschmidt K Am J Emerg Med; 2012 Sep; 30(7):1320.e5-7. PubMed ID: 21802885 [TBL] [Abstract][Full Text] [Related]
63. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. Robson H; Braund R; Glass M; Ashton J; Tatley M Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704 [TBL] [Abstract][Full Text] [Related]
64. Synthetic Cannabinoids. Mills B; Yepes A; Nugent K Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518 [TBL] [Abstract][Full Text] [Related]
65. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352 [TBL] [Abstract][Full Text] [Related]
66. Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: profiling and relation to sales data. Lyphout C; Yates C; Margolin ZR; Dargan PI; Dines AM; Heyerdahl F; Hovda KE; Giraudon I; Bucher-Bartelson B; Green JL; ; Wood DM Eur J Clin Pharmacol; 2019 Jan; 75(1):77-85. PubMed ID: 30244371 [TBL] [Abstract][Full Text] [Related]
67. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor. Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003 [TBL] [Abstract][Full Text] [Related]
68. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. Banister SD; Connor M Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473 [TBL] [Abstract][Full Text] [Related]
69. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. Wang GS; Buttorff C; Wilks A; Schwam D; Tung GJ; Banerji S; Dart RC; Pacula RL Am J Emerg Med; 2022 Mar; 53():150-153. PubMed ID: 35051702 [TBL] [Abstract][Full Text] [Related]
70. Poor Identification of Emergency Department Acute Recreational Drug Toxicity Presentations Using Routine Hospital Coding Systems: the Experience in Denmark, Switzerland and the UK. Wood DM; De La Rue L; Hosin AA; Jurgens G; Liakoni E; Heyerdahl F; Hovda KE; Dines A; Giraudon I; Liechti ME; Dargan PI J Med Toxicol; 2019 Apr; 15(2):112-120. PubMed ID: 30603897 [TBL] [Abstract][Full Text] [Related]
71. Synthetic cannabinoid use among college students. Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774 [TBL] [Abstract][Full Text] [Related]
72. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Seywright A; Torrance HJ; Wylie FM; McKeown DA; Lowe DJ; Stevenson R Clin Toxicol (Phila); 2016 Sep; 54(8):632-7. PubMed ID: 27213960 [TBL] [Abstract][Full Text] [Related]
73. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158 [TBL] [Abstract][Full Text] [Related]
74. Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons. Rodrigues TB; Souza MP; de Melo Barbosa L; de Carvalho Ponce J; Júnior LFN; Yonamine M; Costa JL Forensic Toxicol; 2022 Jan; 40(1):119-124. PubMed ID: 36454481 [TBL] [Abstract][Full Text] [Related]
75. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020). Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496 [TBL] [Abstract][Full Text] [Related]
76. Concurrent Use of Benzodiazepine by Heroin Users-What Are the Prevalence and the Risks Associated with This Pattern of Use? Yamamoto T; Dargan PI; Dines A; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Sedefov R; Wood DM; J Med Toxicol; 2019 Jan; 15(1):4-11. PubMed ID: 30066312 [TBL] [Abstract][Full Text] [Related]
77. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights. Malaca S; Tini A; Umani Ronchi F Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053 [TBL] [Abstract][Full Text] [Related]
78. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383 [TBL] [Abstract][Full Text] [Related]
79. Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. Bonaccorso S; Metastasio A; Ricciardi A; Stewart N; Jamal L; Rujully NU; Theleritis C; Ferracuti S; Ducci G; Schifano F Brain Sci; 2018 Jul; 8(7):. PubMed ID: 30011896 [TBL] [Abstract][Full Text] [Related]